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FDA Begins Proceedings To Remove
Erythromycin Estolate From Market
November 1979
:Editorial Board
Jere :E. Goyan, PhD, Commissioner
Sherwin Gardner, Deptdy CommWioner
Mark Novitch, MD, Auocuite Commissioner for Heallh Affair,
Wayne L. Pines, Auocuite Commissioner for Public Affairs
J. Richard Crout, MD, Director, Bureau of Drugs
Marion J . Finkel, MD, Associate Director, Bureau of Drugs
CHANGE OF ADDRESS: Address changes for those label, marked with a "Q"
~houl~ be 5'.'nt to ~DA Drug Bu//etin / HFl -20, Rockville, Md . 20857 . If your label
1s ~ot idenufied wnh a "Q" send add ress changes to the professional association to
wh1c~ you belong. _i.e.: American Medical Association, American Osteopathic
Assoc,auon, Amencan Dental Association , American Nu~ Association
American Pharmaceutical Association, American Podiatry Association-, or the Stu :
dent American Pha~aceutical Association. FDA cannot change any address
taken from a professional association mailing list. so check your mailing label
before requesting an address change.

Papaverine and Ethaverine Studies
The effectiveness of products containing papaverine
(Pavabid, Cerespan, Therapav, Pava Time-cap, and
others) and ethaverine (Isovex-100, Ethaquin, Ethatab,
Cebral, and others) has recently been challenged by an
FDA advisory committee.
FDA's Peripheral and Central Nervous System Drugs
Advisory Committee unanimously concluded in August
that "there is no body of evidence that will support the effectiveness of papaverine and ethaverine for any of their
claimed indications."
The two drugs, which are chemically closely related ,
have been on the market approximately 40 years in
various dosage forms. They are prescribed for cerebrovascular, cardiovascular, and peripheral vascular problems,
primarily in elderly patients. However, they had never
been evaluated in accordance with the provision of the
Federal Food, Drug, and Cosmetic Act that requires adequate and well-controlled studies demonstrating effectiveness.
After reviewing studies submitted by several manufacturers, the Advisory Committee concluded that, although
papaverine and ethaverine may act as vasodilators in
animals and normal human subjects, the studies do not
show that the drugs are effective for the disease states for
which they are presently labeled.
Other data from a study carried out by the University
of Tennessee for FDA's Division of Biopharmaceutics
showed poor bioavailability for the time release
papaverine-containing products. In addition, previous
independent studies indicated that papaverine has a
biological half life of only one to two hours. Approximately 70 percent of an orally administered dose is
metabolized in the liver before reaching the circulatory
system, so that under the best of conditions only 30 per cent of a dose can reach the appropriate site, and even
that is removed quite rapidly.
The Drug Bulletin will keep health professionals informed of any additional evaluations and actions regarding these drugs.

FDA's Bureau of Drugs is initiating formal administrative procedures to remove solid dosage forms of erythromycin estolate (Ilosone) from the market due to a greater
risk of hepatotoxicity than that associated with other
forms of erythromycin. 1 • 4 Still under consideration are
the liquid pediatric dosage forms.
Erythromycin estolate labeling has carried a warning
of the drug's hepatotoxicity since 1962. A stronger boxed
warning was added in 1973, as reported in the January
1974 Drug Bulletin.

History of Problem
The question of removal of the drug from the market
was considered by FDA's Anti-Infective Agents Advisory
Committee in 1973. The Committee recommended that
erythromycin estolate continue to be allowed on the
market because there was a suggestion that the greater
risk of hepatotoxicity with this drug might be outweighed
by a therapeutic superiority over other erythromycin
products by virtue of the higher blood levels it produced.
More recent data indicate, however, that the estolate
does not, in fact, produce higher blood levels of active
erythromycin.
Previous blood level studies had measured erythromycin estolate in the blood. The active fraction, however, is
the free erythromycin base. Bioavailability studies recently carried out for FDA at the University of Texas, using a method which differentiated the free base from the
inactive esters, showed that after single-dose administration of erythromycin estolate and erythromycin stearate
the blood concentration of free base from the estolate
product was only 45 percent of that noted from the stearate product. In a multiple-dose comparison of erythromycin estolate with erythromycin base (5 doses given six
hours apart), after the first dose the blood concentration
of free erythromycin from the estolate was only 36 percent of that from the erythromycin base product. vVith
the fifth dose the concentration from the escolate had increased to 88 percent, but the cumulative concentration
for all five doses was only 69 percent of that achieved with
the erythromycin base product.
Several clinical studies fail to support increased effectiveness of erythromycin estolate in comparison with
other erythromycin products, 1 , 2 and authors of review articles concur.'·•

Adverse Reaction Data
FDA adverse reaction data from 1969 through 1978 include 418 reports of hepatotoxicity due to specified oral
erythromycin products. The data show 93 percent of the
hepatotoxicity occurred in patients receiving erythromycin estolate, and among these for which age was specified, 82 percent of the reactions occurred in patients
12-years-old and older.

Because of the substantially higher rate of hepatic
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reactions with erythromycin estolate in comparison with
other forms of erythromycin, and because the estolate appears to offer no compensating benefits, FDA's Bureau of
Drugs is moving to remove solid dosage forms of erythromycin estolate from the market on safety grounds. Review is continuing on whether, in young children, erythromycin estolate is sufficiently low in toxic effects and has
certain special advantages that would warrant its remaining on the market. The Drug Bulletin will keep health
professionals informed about further developments. This
action does not affect the safer oral erythromycin products containing erythromycin base, erythromycin stearate, or erythromycin ethylsuccinate.
References:
l. Brown, ST, et al: Comparison of erythromycin ba~ and ~tolate in
gonococcal urethritis.JAMA 238 (13): 13il -3. 1977 .
2 . Billow . BW . et al: A clinical study of erythromycin: a comparative
evaluation of ~veral salts. CuTT Ther Res 6: 381·-1. 1964 .
3. Ginsburg . CM. and Eichenwald. HF: Erythromycin: a review of its
uses in pediatric practice.] Pediatr 89 (6): 872 -8-1. 1976 .
4 . Eichenwald, HF, and McCracken. Jr .. GH: Antimicrobial therapy
in infants and children. Part I. Review of antimicrobial agents] Pediatr
93 : 337-56, 1978 .

Dantrolene Sodium Approved
for Malignant Hyperthermia
FDA has approved intravenous dantrolene sodium
(Dantrium) for treatment of malignant hyperthermia
syndrome, a rare genetically determined condition
precipitated by inhalants and neuromuscular blocking
agents used during general anesthesia and by other
stressful situations. Previously, no specific drug product
was commercially available to treat this condition which
had a mortality rate of 50 to 70 percent. 1 • 2
Intravenous dantrolene sodium is a new formulation of
the product which has for some time been approved in
oral form for use as a direct muscle relaxant in controlling the manifestations of clinical spasticity resulting from
upper motor neuron disorders.
During malignant hyperthermia, skeletal muscle undergoes contraction as a result of release of calcium from
the sarcoplasmic reticulum in response to drugs or stress.
It is postulated that dantrolene might decrease the
amount of transmitter released by the excitation-contraction coupling process and thus indirectly reduce the
amount of calcium released, resulting in a reversal or
decrease of the manifestations of the hyperthermic crisis.

of the condition may be the too rapid heating of the carbon dioxide canister on the anesthesia machine. The condition may develop unexpectedly, even in patients with a
past history of several uneventful anesthetic administrations, but it is most frequently encountered in individuals
with a family history suggestive of similar events.

Known Supportive Measures Necessary
Intravenous dantroiene sodium should be administered
as soon as the malignant hyperthennia reaction is
recognized. However, it is not a substitute for known supportive measures, which continue to be necessary. These
include, in most cases, discontinuing the suspected triggering agents, attending to the increased oxygen requirements, managing the metabolic acidosis, instituting cooling when necessary, assuring adequate urinary output,
and monitoring for electrolyte imbalance.
After studies in susceptible experimental animals,
which established that intravenous dantrolene reduced
the mortality and alleviated the signs of ,nalignant hyperthermic crisis, 3 the drug product was widely distributed
to clinical investigators in the United States, Canada, and
other countries for use in emergencies and for standby in
susceptible individuals. The clinical data established that
intravenous dantrolene is effective in alleviating the signs
of malignant hyperthermic crisis in humans, just as it is in
susceptible animals. All patients who were treated early
in the crisis recovered when intravenous dantrolene sodium was used along with intensive supportive treatment.
Until an adequate supply can be assured through regular marketing channels, the manufacturer of Dantrium,
Nonvich-Eaton, has established a hotline for emergency
requests for specific patients believed to be susceptible to
malignant hyperthermia. The number is (607) 335-2133.
Referenus :
l. Britt , BA . and Kalow, W : :'-lalignant h yperthermia; a statistical
re\'iew . Canad Anaesth Soc], 17 : 293-3 15, 1970.
2. Britt. BA; et al: Chapter 5 of Malignant HypertheTmia, CurTent
Concepts, ed. by E. 0. Henschel, pp. 63-67. Appleton-Century-Crofts.
N.Y . . 19i1 .
3. Gronert , GA : MildeJH; Theye. RA : Dantrolene in porcine malig •
nant hypenhermia. Anesthesiology 4-1 (6): ·188-95, 1976.

Problems with B 12
Radiodilution Assays
Physicians, laboratory personnel, and other health
professionals should be aware that commercial radiodilu•
tion assays may not provide an accurate measure of
vitamin Bu (cobalamin) serum levels.
FDA recently convened the Clinical Chemistry and
Hematology Devices Panel to discuss reports that the
assays are not specific for vitamin B 1 z. These reports have
indicated that B 12 analogs were being measured as true
Bu , resulting in falsely elevated serum B 12 measurements
that could mask vitamin Bu deficiency .
This would result in approximately 20 percent of patients with B 12 deficiency not being diagnosed if clinicians
relied upon only the results of the assays. Failure to
diagnose and treat a B 12 deficiency can result in irreparable neurologic damage . Vitamin Ba deficiency is also

Signs of Malignant Hyperthermia
Primary signs of malignant hyperthennia include:
tachycardia, tachypnea, increased arteriovenous oxygen
difference with systemic arterial hypoxia, hypercarbia,
and metabolic acidosis. Other signs which may be present
are: cardiac arrhythmias, cyanosis, skin mottling, fever,
rigidity, profuse sweating. unstable blood pressure,
hyperkalemia, myoglobinemia, and elt:vated creatine
phosphokinase (CPK). Fever is not always present early in
the syndrome and it may be absent altogether.
Malignant hyperthermia is a condition which is now
diagnosed more frequently than previously, and which
manifests itself at various levels of severity. The first sign
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related to macrocytic anemia, pernicious anemia, and
megaloblastic anemia.

Reasons for Lack of Specificity
The lack of specificity was due to the Bn binding protein used. Intrinsic factor binds only B 12 ; R protein binds
both Bu and B 12 analogs. The 10 assays studied employ
mixtures of R protein and intrinsic factor, with R protein
content ranging from 51 percent to 85 percent. An additional difficulty is that intrinsic factor loses 10 percent of
its Bu binding capacity at a pH of 4.0 and greater than
98 percent at pH 2.0. Five commercial assays were carried out at a pH of 2.0 or less and therefore any intrinsic
factor present was essentially eliminated.
Acting upon the panel's recommendations after a
review of the data, the Agency contacted manufacturers
of B 12 radiodilution assays and requested that they immediately evaluate their products for the potential erroneous results and subsequent misdiagnoses. FDA asked
the manufacturers to notify it of the results of the evaluations and of the need for product modification and/or
labeling revision. FDA also asked the manufacturers to
provide their customers with information sufficient for
the safe and effective use of the assays. The manufacturers have informed their customers of the potential
problems with their assays and several manufacturers
have modified their product.

Task Force Established
In addition, FDA has requested that the National
Committee for Clinical Laboratory Standards (NCCLS)
establish a task force to develop a voluntary standard for
vitamin Bu radiodilution assays. A preliminary draft of
the NCCLS standard was reviewed favorably by the
Panel.
FDA requests that physicians, laboratory personnel,
and other health professionals report any difficulties with
radiodilution assays for vitamin Bu to Kaiser Aziz,
Ph.D., Bureau of Medical Devices, Food and Drug Administration, HFK-440, 8757 Georgia Avenue, Silver
Spring, MD 20910; phone (310) 427-7550.

Reports of Injuries
FDA's Bureau of Radiological Health has received reports of more than 460 injuries in the past four years.
Most of the patients in these cases complained of considerable pain and eye discomfort. A diffuse punctate
keratitis involving the cornea is the most prominent
clinical finding in such cases. Skin erythema is the other
major clinical finding. Increased sensitivity to this radiation is likely in individuals who are sensitive to sunlight or
who are on medication such as tetracyline which could
make them photosensitive. Bioeffects studies, including
epidemiological studies of human populations, also indicate possible long-term effects of ultraviolet (UV)
radiation, such as premature skin-aging and malignant
skin tumors as a result of prolonged or repeated
exposure.•
Injuries occur when the protective outer glass bulb of
these lamps is broken, permitting an exposure to shortwave UV radiation. Most such injuries occur following
continuous exposure for several hours at a distance of up
to six meters from the damaged lamp. These lamps can
continue to operate and emit hazardous UV radiation for
many days.

Performance Standard
To promote the safety of mercury vapor lamps, FDA
has developed an equipment performance standard.
Manufacturers of lamps sold for use in areas where individuals may be exposed to lamps for extended periods
must provide an automatic mechanism to shut off the
lamp in case the outer bulb is damaged. Labeling for
these lamps should state:

This lamp should self-extinguish within 15 minutes after the outer envelope is broken or punctured.
If such damage occurs, TURN OFF AND REMOVE
LAMP to avoid possible injury from hazardous shortwave ultraviolet radiation.

Manufacturers of lamps sold for uses where injury from a
broken lamp is unlikely may avoid incorporating a shut
off, but must clearly state such restricted use in all labeling and advertising. For lamps that do not shut off
automatically, the labeling should state:

Reference :
I. Kolhou~. JF: Kondo. H ; Allen. NC, et al: Cobalamin analogues
are present in human plasma and can mask cobalamin deficiency
because current radioisotope dilution assays are not specific for true
cobalamin, N Engl J Med 299: 785 -792, 1978.

New Standards Established
For Mercury Vapor Lamps

WARNING:
This lamp can cause serious skin burn and eye inflammation from shortwave UV radiation if outer
envelope of the lamp is broken or punctured. Do not
use where people will remain for more than a few
minutes unless adequate shielding or other safety
precautions are used. Lamps that will automatically
extinguish when the outer envelope is broken or
punctured are commercially available.

A mandatory safety performance standard for mercury
vapor lamps has been established by FDA.
Over 25 million high-intensity mercury vapor discharge lamps are presently in use in the United States.
These lamps are used for roadway lighting, sports arenas,
school gymnasiums, parking areas, warehouses, and
retail establishments, as well as home use to light yards,
patios, and driveways.
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.The safety standard applies to lamps manufactured
after March 6, 1980.
·
This new standard is designed to permit the continued
use of vapor lamps while providing adequate protection
to the public if the outer bulbs are damaged.

against levodopa-induced cardiac arrhythmias_
Although Merck, Sharp and Dohme is not yet marketing carbidopa alone, FDA approved its use in 1977 and
it is available to physicians from the manufacturer upon
request.

Medical Treatment Needed

Clinoril Adverse Reactions

The Agency recommends that individuals exposed to
UV radiation from a damaged lamp should see a physician if symptoms of skin burns or eye irritation occur. Individuals using mercury vapor or metal halide lamps in a
home or yard should consider replacing them with those
that have a safety shut-off feature. An alternative is to install a UV radiation-absorbing shield over the lamp
reflector.
Physicians who treat patients with keratitis and/or
erythema for which some doubt exists about the cause
should inquire about possible exposure to these high-intensity lamps. FDA would appreciate receiving reports of
injury when potential exposure has been confirmed. Send
reports to:

Numerous adverse reaction reports received by FDA
indicate that sulindac (Clinoril) has side effects similar to
those of indomethacin (Indocin). This might be expected
since sulindac is an isostere of indomethacin.
A nonsteroidal, anti-inflammatory agent, sulindac has
received widespread use since it was first marketed in
November 1978. FDA has received reports of the following adverse reactions to sulindac: congestive heart
failure, Stevens-Johnson syndrome, toxic epidermal
necrolysis, bone marrow depression, thrombocytopenia,
leukopenia, gastrointestinal perforation, nephropathy,
and pancreatitis. Reported adverse ocular effects include: diplopia, cloudy vision, eyeball swelling, noninflammatory ulceration of the cornea, retinal hemorrhage, blurred vision, and spots before the eyes.
The majority of these effects have also been reported in
association with use of other nonsteroidal anti-inflammatory drugs, but most of them are not yet mentioned in the
present labeling of sulindac.
FDA is currently analyzing data to identify factors
which may predispose patients to risk of these reactions.
Physicians and other health professionals who note
adverse reactions to the drug should report them to:

Division of Biological Effects, HFX-140
Bureau of Radiological Health
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857
Reference:
I. Federal Register. Vol. 43. l'\o. 78. Friday. April 21. 1978.

Carbidopa Available
As Single Agent
Physicians treating patients with idiopathic Parkinson's
disease, postencephalitic parkinsonism, and symptomatic
parkinsonisrn should be aware that carbidopa (Lodosyn)
is now available as a single agent from Merck, Sharp and
Dohme.
Carbidopa can be used in combination with levodopa
or with levodopa/carbidopa combinations (Sinemet) to
lessen the side effects of levodopa and, in some patients,
to achieve greater effectiveness or a smoother therapeutic
response.
Carbidopa can be used to augment the levodopa/carbidopa preparation or with levodopa alone, in patients
who require a ratio other than the l: 10 carbidopa to
levodopa present in Sinemet. It is also useful for patients
who need to be titrated on the individual ingredients
before being given the combination, and for those who
need only low doses of levodopa and do not, therefore,
recei\·e enough carbidopa when given the combination.
Carbidopa is a dopa decarboxylase inhibitor. When
administered with levodopa, carbidopa decreases the
dosage requirement of levodopa by at least 75 percent
and reduces the incidence of certain side effects
associated with high-dosage levodopa therapy, such as
anorexia , nausea, and vomiting. In addition, there is suggestive evidence that it may provide some protection

Division of Epidemiology and
Drug Experience (HDF-210)
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Pediatric Tetracycline Use
Reports of adverse reactions in children given
tetracycline liquid and tetracycline liquid congeners continue to be of concern to health professionals.
When pediatric tetracycline drops were withdrawn
from the market in 1978, other liquid forms were allowed
to remain, primarily because they were needed for
geriatric patients (see May-July 1978 Drug Bulletin).
However, the figures from the July 1978 - June 1979
National Disease and Therapeutic Index show that 60
percent of the prescriptions for tetracycline liquid are
written for children from 0 to 9 years old, while geriatric
patients over age 65 account for only 6 percent of the
prescriptions. Similarly, 80 percent of the prescriptions
for tetracycline congener liquid are written for children
under the age of 9.
Tetracycline liquid and tetracycline congeners liquid
may cause depression of bone growth and permanent discoloration of the teeth, as well as enamel hypoplasia,
when given during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years).
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Therefore, tetracycline should not be used in this age
group unless other drugs are not likely to be effective or
are contraindicated.
Tetracycline congeners include: oxytetracycline (Terramycin).
chlortetracycline (Aureomycin),
demeclocycline (Declomycin), doxycycline (Doxy-II,
Vibramycin), methacycline (Rondomycin), and
minocycline (Minocin, Vectrin).

Medical Device and Laboratory
Product Problem Reporting Program
(PRP)
Health care professionals can now dial a toll-free
WA TS number to report problems that they experience
with medical devices and in vitro diagnostic products.
The number is (800) 638-6725 (in Maryland , call collect
(301) 881-0256). Callers should be ready to furnish the inform ation requested on the tear-out reporting form in
this Drug Bulletin.
FDA encourages the health care community to report:
•
•
•
•
•
•
•
•
•
•

hazardous or potentially hazardous products
improper labeling
incomplete or confusing instructions
erroneous information
designs that encourage human error
performance failures
non-sterile products
packaging errors
defective components
other situations that could affect the safety and
efficacy of a device.

FDA 's problem reporting program covers only product-related defects, and information concerning patients
is not requested.
Device and diagnostic problem reports help FDA determine when a product poses an actual or potential
hazard to health, which sometimes results in a recall. The
Agency also uses this information to detect recurring
problems, and to become aware of device deficiencies.
These data are also useful in developing profiles, performance standards, and detecting trends of manufacturer/
product problems.
FDA piloted the problem reporting program in 1973 to
collect data on problems in clinical laboratories. The

U.S. Pharmacopeia operates this program under contract
with FDA's Bureau of Medical Devices.

Infant Formulas
Over the past several months, infant formulas have
been involved in an increasing number of health-related
problems. Ranging from nutrient deficiencies to processing breakdowns, these events have served to focus attention on procedures necessary to assure the quality and
safety of these products.
FDA advises that all hospitals and other health
facilities immediately begin to evaluate their procedures
for storage, distribution, and preparation of infant formulas to identify possible points of contamination and/or
reduction in nutritive value.
In addition, FDA needs to have more information on
infant illnesses in which formulas may be implicated. The
Agency - would welcome information on the clinical
nature of such illnesses, any supportive laboratory findings, the product or products that may be involved, the
time that the problem occurred, and the length of time
the formula was used. This information should be sent to
FDA's Bureau of Foods, HFF-1, 200 C Street, S.W.,
Washington, D.C. 20204.
FDA is reevaluating its procedures for assuring the
quality and nutritional efficacy of infant formulas. The
Agency is considering the establishment of standards for
nutritional quality, as well as development of procedures
for requiring premarket clearance of such formulas.
FDA also is considering the establishment of required
quality assurance checks as part of good manufacturing
practice for each such product. Ea·rly in 1980 , FDA will
hold the first of a series of international conferences to
determine which nutrients need to be checked routinely
and which nutrients need to be evaluated only under
special conditions. In addition, these conferences will explore the scientific basis for construction of these standards.

ERRATA
"Update on Amphetamine Abuse and Labeling" in
the September 1979 Drug Bulletin (Volume 9, Number 4)
incorrectly identified phenmetrazine as a Schedule III
drug. Phenmetrazine is a Schedule II drug. The anorectic phendimetrazine, however, is a Schedule III drug.
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staple or seal with tape;
No postage is necessary.

The Agency appreciates receiving this type of
input from physicians and other health professionals.

,,;

•
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ACCESS
MEDICAL DEVICE AND LABORATORY PRODUCT
PROBLEM REPORTING PROGRAM

DATE

7
1 TRADE NAME AND TYPE OF PRODUCT (All~h labeling. if available)

2 PRODUCT IDENTIFICATION
LOl NO

SERIAL NO

PRODUCT NO

3. NAME AND ADDRESS OF MANUFACTURER

4. EXPIRATION DATE (II applicable)

5 YOU R NAME

6 YOUR FACILITY S NAME. ADDRESS. AND ZIP CODE

AREA CODE AND PHONE NUMBER OF YOUR FACILITY

7 PROBLEMS NOTED OR SUSPECTED

RETURN TO
United States Pharmacopeia
12601 Twinbrook Parkway
Rockville, Maryland 20852
Attention: Dr. Joseph G. Valentino

OR

CALL TOLL FREE ANYTIME

800-638-6725 *
IN THE CONTINENTAL UNITED STATES

•1n Maryland. call co1Iec1 (301)881-0256
between 9.00 At.I and 4 30 Pi.A
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I 3
Dr . E. R. Owens
Medical Director
Ownes-Franklin Health Center
Prairie View A&M University
Prairie View,TX 77445
Dear Dr. Owens :
Recently this office requested that you complete and submit a student employment form indicating the positions available in your department , a brief job
description, number needed, and hours required .
As of this date you have failed to return the request to the Student Empolyment
Office .
I am enclosing another request form which you should complete and return to
the Student Employmenl Office by Monday , September 17, 1979 . Your payroll for
the month of September will not be accepted unless the request form is on file .
Sincerely,

A. D. James, Jr . , Director
Student Financial Aid
ADJJ/wes
Enclosure
cc :

Dr . A. I . Thomas
Mr . G. W. Kendrick
Mr . F . C. Yepp
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